- xLM's ContinuousTV Weekly Newsletter
- Posts
- #061: AI Meets GxP Manufacturing: Discover AI in GxP at xTelliGent Two
#061: AI Meets GxP Manufacturing: Discover AI in GxP at xTelliGent Two
š Date: May 28, 2025 | š» Format Virtual | Get ready to explore how autonomous AI is revolutionizing GxP compliance, validation, and pharmaceutical operations. The xTelliGent Two: AI in GxP 2025 Summit unites pioneers, innovators, and practitioners from leading organizations to showcase real-world applications of AI in the life sciences sector.

Table of Contents
1ļøā£21 Speakers from the US, UK, Canada, Belgium....
2ļøā£600+ Registrants from over 14 countries
3ļøā£20 Sessions: Live Demos, Case Studies, Practical/Responsible AI for GxP Manufacturing
4ļøā£Speakers from Amgen, xLM, Abzena, SCA Pharma, SalesForce, BenchSci, Funartech and moreā¦
Hereās an exclusive look at few of the groundbreaking sessions poised to redefine possibilities in GxP manufacturing:
1.0 Tackling Complex Data Challenges in AI-Driven Life Sciences
One of the sessions will address the intricate challenges of deploying large language models (LLMs) in biomedical settings. While LLMs are powerful, they often encounter difficulties with domain-specific language, noisy or sparse datasets, and critical decision-making scenarios.
Key discussion points for this session will include:
The necessity for grounded, domain-aware AI systems
The significance of transparency, reproducibility, and evaluation
The advantages of simpler, traditional ML models and specialized tools for prompt orchestration and entity recognition

The main takeaway? Organizations should ask: āWhatās the simplest solution that actually works?ā
2.0 Building AI the Right Way in Regulated Environments
Another session will focus on the strategic, organizational, and technical foundations essential for sustainable AI in life sciences. It has been observed that many AI projects failānot due to inadequate models, but rather because of insufficient structure, planning, and cultural alignment.
Key discussion points for this session will include:
Strong leadership commitment and cross-functional collaboration
A robust data infrastructure and data governance
A focus on AI literacy, change management, and ethical considerations
The importance of building resilience into AI systems for long-term scalability

Participants will be reminded that adopting AI is not merely a quick fixāit represents a long-term transformation that requires clarity, governance, and active employee involvement.
3.0 Unlocking New Possibilities in Digital Pathology
AIās impact on modern pathology will also be a critical focus, showcasing how AI enhances diagnostic accuracy, efficiency, and personalization in cancer care. Attendees will learn how computer vision models are being developed to identify microscopic tumor patterns, grade cellular abnormalities, and interpret immune responses from digitized slides.
Key discussion points for this session will include:
Ensuring consistency in diagnostic output
Providing interpretable biomarker insights
Functioning on scanner-independent platforms validated across diverse patient populations

These innovations are transforming pathology from a manual art into a precision scienceāfacilitating quicker, better-informed decisions in clinical environments.
4.0 Explore the Next Frontier of AI in GxP Manufacturing
The summit will feature a diverse lineup of sessions and live demonstrations that highlight how AI is transforming the GxP ecosystemāfrom intelligent agents and validation engines to compliance automation and ML-powered decision support.
Youāll gain insights into:
Designing AI-first strategies for regulatory environments
Implementing agentic frameworks for intelligent automation
Balancing innovation with governance, traceability, and risk mitigation
Real-world success stories from organizations scaling AI within GxP boundaries
Whether youāre involved in quality assurance, IT, compliance, or strategy, xTelliGent Two is your gateway to building smarter, faster, and more reliable operations using AI.
Reply